ATOPIC DERMATITIS (ECZEMA)

This study looked at the long-term safety of a cream called roflumilast for people with mild to moderate eczema (atopic dermatitis). Over 1,200 participants, ages 2 and up, applied the cream once daily for up to 52 weeks. The main goal was to track any side effects, with secondar…

This study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…

This study compared an online, team-based care model to standard in-person care for managing atopic dermatitis (eczema). 300 patients were randomly assigned to either online or in-person care for 12 months. The goal was to see if the online approach could match in-person care in …

This study tested whether a supplement containing L-histidine, along with a topical oil or lotion and unscented soap, could improve mild-to-moderate eczema in children. Forty children ages 1 to 12 were split into two groups: one received a powder supplement and the other a gummy …

This phase 2 trial tested a gel called HY209 on 210 adults with mild to moderate atopic dermatitis (eczema). The study compared different strengths of the gel to a placebo to see if it could reduce skin redness, itching, and rash. Results will show whether the gel is safe and eff…

This study tested a cream called ARQ-151 on 652 children aged 2 to 5 with eczema (atopic dermatitis). The cream was applied once daily for 4 weeks. The goal was to see if it could clear or nearly clear the skin rash better than a cream with no active ingredient. The study is comp…

This study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to 2 years with mild-to-moderate eczema. The main goal was to see if the cream is safe and well-tolerated. Researchers tracked side effects, serious side effects, and …

This study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effec…